Well, its been a long wait at #AAZ but no matter how you look at it, the new mines, one of which produces 120k oz annually and has reserves of 8m oz must surely make the company worth at least 2.5 times what it was worth 6 months ago, when it was producing 80k oz
of course it will take time to get everything productive, but the RNS today shows a huge increase in resources and the prospect of a real acceleration at Ordubad, which is a huge, 45m oz resource that has been stuck in an enclave and hard to progress. Upshot is, current SP
of 155p is still incredibly cheap. I think £3 quite attainable in weeks, and I expect much higher by the end of the year. Plus you get a dividend of 9c last year (with a special still to come) to keep you entertained. My biggest holding, by some way. And I will add
that my biggest criticism of @AAZMining is that the board are very conservative. I think some of you miserable lot might take that as a positive!
• • •
Missing some Tweet in this thread? You can try to
force a refresh
@AAZMining is my biggest holding and I don't think everyone appreciates the opportunity it offers. Its unlike most miners as it produces metals rather than shares: gold and copper. Shares in issue were 112m in 2014, now 114m. Market cap £184m, SP 160p. Since 2018 #AAZ has paid
dividends of 19.5c, with 9c paid in 2020 and a special dividend expected to be declared very soon. They have no debt and at year end near $40m of cash. 2020 was a year when everything went wrong - pandemic followed by war - and they missed production targets as key staff
were conscripted, but they still produced 70k GEO. Before the war they were guiding 25k oz production in Q4 as they dug into better grades at their flagship mine. AAZ had rights over 3 mines in occupied territories that nobody had thought had any value. Suddenly
#DDDD is a big holding for me that I built between March and, well, last Friday. A lot of people think of it as a pharma company with the attendant risks of drug development. I don’t think that’s right. My understanding is that @4dpharmaplc have a huge amount of data
concerning the make up of gut bacteria in people with various conditions and “healthy” people. From analysis they can see what bacteria are dominant and which are missing among those with afflictions. But crunching the data is key, as is the philosophy of using
Bacteria that occur naturally in the gut. So it is a data driven, bottom up (almost literally) process, where the biome of the ill pinpoints what they are missing. As a result, I think the risk of phase 2/3 failure is much lower than in traditional pharma. There is